

 Content archived on 2024-05-15



Innovative therapeutics for the prototype autoimmune disease, myasthenia gravis

Fact Sheet

Project Information

IMMUNOTHERAPEUTICS

Grant agreement ID: QLK3-CT-2001-00225

Project closed

Start date

1 January 2002

End date

31 December 2005

Funded under

Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Total cost

€ 2 466 845,00

EU contribution

€ 1 822 984,00

Coordinated by

HELLENIC PASTEUR INSTITUTE
 Greece

Objective

We will develop novel, specific, therapeutics to treat the model autoimmune disease, myasthenia gravis, which is caused by antibodies to the muscle acetylcholine receptor (Ache). The therapeutics (to be tested extensively in vitro and in vivo experiments) will target different aspects of the immune response and involve

- (a) ex vivo immunoadsorption of the anti-Ache antibodies by immobilized polypeptide fragments of the Ache;
- (b) protection of the Ache and reduction of B cell activation by modified non-pathogenic engineered monoclonal anti-Ache antibodies;
- (c) selection of active subtractions of normal human lag for in vivo intravenous lag

(Ivy) therapy; (d) induction of mussel tolerance by the use of recombinant Ache polypeptides;
(e) peptide vaccination against a dominant T cell receptor;
(f) peptide:MHC multimedia complexes to identify T cells ex vivo and tolerate them in vivo; (9) antilogous, Specific-specific, tolerogenic dendrite cells for in vivo use;
(h) combinations of selected therapies; (I) for the more efficient therapies, we will study gene expression levels by micro array technology in order to explore their mechanisms of action, and to identify potential new drug targets.

Fields of science (EuroSciVoc)

[natural sciences](#) > [biological sciences](#) > [biochemistry](#) > [biomolecules](#)

[medical and health sciences](#) > [basic medicine](#) > [immunology](#) > [autoimmune diseases](#)



Programme(s)

[FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002](#)

Topic(s)

[1.1.1.-3. - Key action The "Cell factory"](#)

Call for proposal

Data not available

Funding Scheme

[CSC - Cost-sharing contracts](#)

Coordinator



HELLENIC PASTEUR INSTITUTE

EU contribution

No data

Total cost

No data

Address

127,Vassilissis Sofias Av. 127
11521 ATHENS

 Greece 

Participants (7)



CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 France

EU contribution

No data

Address

Avenue de la Resistance 133
92350 LE PLESSIS-ROBINSON 

Total cost

No data



DIAMED EUROGEN N.V.

 Belgium

EU contribution

No data

Address

Transportstraat 4
3980 TESSENDERLO 

Total cost

No data



KAROLINSKA INSTITUTE

 Sweden

EU contribution

No data

Address

Solnavagen 1
171 77 STOCKHOLM 

Total cost

No data



THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 United Kingdom

EU contribution

No data

Address

John Radcliffe Hospital, Headley Way
OX1 2JD OXFORD 

Total cost

No data



UNIVERSITE DE PARIS-SUD XI

 France

EU contribution

No data

Address

Avenue de la Resistance, 133 - Hopital Marie Lanne
92350 LE PLESSIS-ROBINSON 

Total cost

No data



UNIVERSITY OF MAASTRICHT

 Netherlands

EU contribution

No data

Address

Dr Tanslaan 10

6229 ET MAASTRICHT 

Total cost

No data



WEIZMANN INSTITUTE OF SCIENCE

 Israel

EU contribution

No data

Address

Herzel Street 2

76100 REHOVOT 

Total cost

No data

Last update: 12 April 2005

Permalink: <https://cordis.europa.eu/project/id/QLK3-CT-2001-00225>

European Union, 2025